Trishula Therapeutics

Who owns Trishula Therapeutics?

Trishula Therapeutics is currently owned by Abingworth through Abingworth Bioventures VII (2018 vintage), since 2020.

Hand-verified · updated 2026-06-10

About Trishula Therapeutics

Trishula Therapeutics is a South San Francisco based clinical-stage antibody company developing cancer immunotherapies that target immune-evasion mechanisms in the tumor microenvironment. Its lead program, TTX-030, is a first-in-class anti-CD39 antibody that inhibits CD39, the enzyme converting ATP to AMP, thereby limiting the build-up of immunosuppressive extracellular adenosine while preserving immune-activating ATP. The company positions the asset within the adenosine-pathway field of immuno-oncology, where CD39 and CD73 act upstream of adenosine-mediated T-cell suppression. TTX-030 has been evaluated as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy, and is advancing in a randomized Phase 2 study in frontline metastatic pancreatic cancer.

Ownership journey

Trishula was established in August 2020 as a spinout of Tizona Therapeutics, created to carry forward the CD39 program that had been part of Tizona's portfolio, with Scott Clarke named as initial chief executive and Anil Singhal later leading the company as CEO. Shares in the new company were distributed to Tizona's existing investors, and the venture syndicate has included Abingworth, which backed the business through its life-sciences funds, alongside MPM, Canaan Partners, InterWest Partners, Lightstone Ventures and AbbVie Ventures. Abingworth's involvement dates from the 2020 formation, with Kurt von Emster acting as the partner overseeing the investment. As a minority venture backer among several institutional shareholders, Abingworth does not control the company, and Trishula remains a privately held, venture-backed business with no exit or secondary transaction recorded.

Under PE ownership

Since its 2020 formation and the venture backing that accompanied it, Trishula has concentrated on maturing TTX-030 through clinical development rather than broadening into a multi-asset platform. The company reported promising early Phase 1b data in 2022 for gastric and gastroesophageal-junction cancers in combination with chemoimmunotherapy, and in November 2023 initiated a randomized Phase 2 trial in frontline metastatic pancreatic cancer. The lead antibody has advanced under a collaboration with AbbVie, which supports its development and provides a strategic partner for the anti-CD39 approach. Progress has therefore been measured in clinical milestones, moving TTX-030 from first-in-human Phase 1/1b studies into a controlled Phase 2 setting in a high-need tumor type.